Why Option Care Health Stock Skyrocketed on Tuesday
Option Care Health (OPCH) shares surged 33% on Tuesday after announcing a $5.8B acquisition by McKesson (MCK) and Clayton, Dubilier & Rice. The deal values OPCH at $32.05 per share, a 37% premium over Monday's close. The transaction is expected to close in early 2027, pending approvals. McKesson will hold 49% of OPCH, with CD&R owning 51%.
How this was made
The 30-second read
Why it matters
The deal creates a larger integrated infusion platform and may set a valuation benchmark for similar providers.
Market read
A large M&A deal in the healthcare services sector with immediate price impact.
What to watch
Regulatory approval risk and CD&R's future exit option could affect valuation.
Background
Option Care Health, the largest independent home infusion provider, agreed to be bought by McKesson and private‑equity partner CD&R for $5.8 billion.
Ticker impact
Option Care Health announced it will be acquired by McKesson and CD&R for $5.8 billion, sending the stock up 33% intraday.
upward pressure as the market prices in the 37% acquisition premium
Deal announced today with a sizable premium; investors are buying on the news.
McKesson disclosed a $5.8 billion acquisition of Option Care Health, expanding its home infusion business.
modest upside as investors assess integration benefits
Acquisition adds a new business line; market impact depends on execution and financing.
Market effects
Adds scale to the home infusion and specialty care sector, potentially boosting peers.
U.S. healthcare services market sees consolidation activity.
Limited to U.S. healthcare investors; no broader macro effect.
Counterpoint
The premium may be excessive if integration costs rise, suggesting a pull‑back risk.
Key entities
- companyOption Care Health
Target of the acquisition, stock surged 33% on announcement.
- companyMcKesson Corp.
Acquirer, expanding its specialty care footprint.
- private equityClayton, Dubilier & Rice
Co‑buyer, will hold majority stake post‑transaction.
